Robotic Surgery Leader EVP Sells $16 Million Stake Near $500 Mark

Intuitive Surgical, Inc. (Nasdaq: ISRG) Executive Vice President and Chief Medical Officer Myriam Curet sold 2,345 shares of company stock through a trust account on February 27 at about $499.71 per share, generating roughly $11.7 million (approximately KRW 1.6 billion) in proceeds. In addition, vesting of RSUs and PSUs, along with share withholding for tax obligations, led to sequential adjustments in the trust’s holdings. Earlier, on February 10, routine compensation and tax-related transactions—including RSU vesting, stock option exercises, partial share sales, and tax withholding—were carried out by Curet and other executives, such as the Senior Vice President of Manufacturing and Supply Chain.

In its fourth-quarter 2025 results, Intuitive Surgical reported revenue of $2.87 billion and non-GAAP EPS of $2.53, outperforming market expectations. Following the February 25 announcement, the share price rose by about 2%, rekindling investor interest. However, the company’s projected 13–15% growth rate in Da Vinci robotic surgery procedures for 2026, its high valuation, and insider share sales of around $30 million over the past 90 days have contributed to volatility in the stock—trading near the $500 level since the start of the year.

Intuitive Surgical is a leader in minimally invasive surgery, developing, manufacturing, and servicing the da Vinci robotic surgical system. In 2025, it generated approximately $10.06 billion (about KRW 13 trillion) in revenue, a substantial portion of which came from recurring consumables and service contracts. With a vast global installed base of da Vinci and Ion systems, the company enjoys high margins and strong cash flow. It is also expanding its portfolio with the Ion platform for pulmonary lesion diagnosis and associated AI-driven navigation software.